January 4, 2023

Pharmaceutical Company to Produce Affordable Insulin in Petersburg

12 On Your Side logo

January 24, 2023

AmerisourceBergen Kicks Off Strategic Relationship with Civica

AmerisourceBergen will serve as Civica, Inc.’s exclusive distribution partner, providing supply chain support for Civica’s products and working to ensure that Civica’s crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.

Civica-Amerisource distribution partnership logos

Media Coverage

AmerisourceBergen Kicks Off Strategic Relationship with Civica
AmerisourceBergen Kicks Off Strategic Relationship with Civica

January 31, 2023

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”

Civica-YPSOMED Partnership logo

Media Coverage

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
Civica Partners with Ypsomed for Insulin Injection Pen

February 8, 2023

Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg

Petersburg is at the center of a nonprofit’s push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city and expects to begin retail sales in 2024.

Civica manufacturing building

Media Coverage

Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg
Game-changing Moves in Petersburg to Produce Affordable Insulin (Please advance video to 12:00)

March 18, 2023

California Selects Civica Rx as Its Insulin Manufacturing Partner

California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom, announcing the state’s choice of Civica to manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative. “We are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.”

(Please advance video to 22:00)

Media Coverage

California Selects Civica Rx as Its Insulin Manufacturing Partner
Governor Newsom Announces $30 Insulin Through CalRx
California Enters a Contract to Make Its Own Affordable Insulin
California Invests $50M to Partner with Civica Rx on Insulin Manufacturing

April 11, 2023

CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings

CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.

Civicasript-Sortpak partnership logo

Media Coverage

CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings
CivicaScript, SortPak Partner to Package & Deliver Medicines
PackagingConnections logo

April 20, 2023

What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take

The price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for The New England Journal of Medicine, titled “Falling Insulin Prices – What Just Happened?” One: The market is awaiting the entry of certain manufacturers that “don’t benefit from high prices.” Two: Government regulations are making it “costlier” for insulin manufacturers to keep charging their prior prices. Three: Public shaming.

a syringe and vials of insulin

Media Coverage

What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take
Falling Insulin Prices – What Just Happened?

May 3, 2023

CivicaRx Disrupts Out of Control Prescription Medication Pricing

Civica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support.

Media Coverage

Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
techbuzz - utah tech news logo

June 2023

Hard Hats & Hello’s

Celebrating the power of innovation and collaboration with our new neighbors in Petersburg, Virginia, and hearing from the Davis family about the road they travel with Type 1 Diabetes.

June 13, 2023

Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer

Biopharma industry veteran Jay Benson has joined Civica as Chief Manufacturing and Supply Chain Officer, replacing Russ Gall who recently announced his retirement.

Media Coverage

Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
BioSpace logo

July 27, 2023

Lawmakers Seek to Boost Domestic Manufacturing, Taking Action on Critical Drug Shortages

A new bill, the RAPID Reserve Act, would require the Department of Health and Human Services to dole out $500 million in awards for generic drug manufacturing to either US-based companies or member countries of the Organization for Economic Co-operation and Development.

Civica President and CEO Ned McCoy welcomed the bill, saying, “The focus on creating additional safety stock inventory within the supply chain and on upgrading aging generic drug manufacturing infrastructure…have the potential to significantly reduce shortages.”

August 2023

The City of Petersburg, Virginia Releases an Economic Development Video Featuring Civica’s Petersburg Manufacturing Facility

September 5, 2023

Disrupting Drug Market Prices and Supply

Civica Rx Board Chair Dan Liljenquist describes the nonprofit generic pharmaceutical company’s mission, structure and influences on the market, saying, “When market failures are hurting people, new markets should emerge to correct that failure.”

September 6, 2023

Civica Celebrates 5th Anniversary

Today, we celebrate Civica’s 5th Anniversary! Five years of building our talented team and lasting partnerships with likeminded organizations. Five years of delivering on and expanding our mission to make quality generic medications available and affordable to everyone. And, five years of doing what is in the best interest of patients.

We thank the Civica team for all they do to put patients first; our members and partners for their dedication to our shared mission; and the generous donors who are helping to make affordable insulin a reality. We are deeply appreciative and look forward to continuing our work together. Our mission is as important as ever!
Watch this video to see how far we’ve come and what’s next!

Civica 5 year collage

November 1, 2023

Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility

Industry veteran Bouwien Smits will run state-of-the-art production of low-cost insulin as well as dozens of other medicines.

Media Coverage

Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility
Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility
BioSpace logo

November 7, 2023

Civica Rx Named a Best Place to Work

Civica has been named a Best Place to Work by BioSpace, recognized in part for its emphasis on culture and innovation.

Media Coverage

Civica Rx Named a Best Place to Work

December 8, 2023

Civica Testifies on Drug Shortages before the U.S. Senate Finance Committee

Civica was invited to provide insights on drug shortages during a Congressional hearing. In his testimony before the U. S. Senate Committee on Finance, Civica’s Senior Vice President of Public Policy Allan Coukell said, “Make no mistake: Drug shortages are not a passing storm that will soon blow over. After a dozen years, shortages must now be understood as a built-in and permanent outcome of our current system.”

Hear Allan’s opening testimony and view the full hearing (Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective).

Media Coverage

Statement: Civica Testimony on Drug Shortages, U.S. Senate Finance Committee
Lawmakers Sound Alarm About Drug Shortages

Stay tuned!

The members section is currently being built, based on feedback from users like yourself.

login

Not a member yet? Get information on joining here.